Background
There is growing evidence to support the concept that hepatitis C virus (HCV) infection is a risk factor for developing type 2 diabetes mellitus (T2DM) and that diabetes control could affect the prognosis of hepatic encephalopathy.
Objective
To study the relation between type of DM and HCV cirrhosis and to report any relationship between the outcome of hepatic encephalopathy and the glycemic control in the period before precipitation of encephalopathy.
Patients and methods
A total of 30 selected diabetic, HCV cirrhotic patients with age ranging from 43 and 70 years (mean, 55.87 years), admitted to the ICU for hepatic encephalopathy, were prospectively enrolled in this study. Cirrhosis was evaluated according to Child classification, whereas encephalopathy was evaluated according to West Haven criteria as well as Richmond agitation sedation score. Glycated hemoglobin was used to assess the glycemic control in the period before precipitation of encephalopathy.
Results
T2DM was more prevalent than type 1 in association with HCV (83.3% T2DM and 16.7% T1DM). Diabetes control plays no role in increasing the severity of cirrhosis (nonsignificant, with P & 0.249). The diabetic HCV cirrhotic patients admitted for hepatic encephalopathy had shorter ICU stay when DM was well-controlled medically in the period before precipitation of encephalopathy (P & 0.001). Moreover, the mortality was decreased markedly in association with diabetes control (P & 0.01).
Conclusion
HCV viremia had a higher risk of T2DM than T1DM. Diabetes control has no role in increasing the severity of HCV cirrhosis. In HCV cirrhotic diabetic patients, well- controlled DM could improve the ICU outcome (shorter ICU stay and less mortality) when admitted for hepatic encephalopathy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.